PBM
CMPX icon

Propel Bio Management’s Compass Therapeutics CMPX Stock Holding History

Propel Bio Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-228,317
Closed -$434K – 17
2025
Q1 		$434K Buy
+228,317
New +$607K 0.5% 15

Other funds holding CMPX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Propel Bio Management's CMPX Position: Q2 2025 in Review

Propel Bio Management sold out of Compass Therapeutics (CMPX) in Q2 2025, closing a stake of 228,317 shares — an estimated $434K sold.

Propel Bio Management first reported a position in CMPX in Q1 2025 and held it in 1 quarter. The position peaked at $434K in Q1 2025. 103 funds tracked by Wall St. Rank hold CMPX as of Q2 2025.

  • Propel Bio Management reported no remaining Compass Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Propel Bio Management sold 228,317 Compass Therapeutics shares in Q2 2025, an estimated $434K.
  • Propel Bio Management first reported a position in Compass Therapeutics in Q1 2025 and held it in 1 quarter.
  • Propel Bio Management's Compass Therapeutics position peaked at $434K in Q1 2025.
  • 103 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2025.

Based on Propel Bio Management's 13F filing for Q2 2025, filed 13 Aug 2025.